Incyte Corporation logo

Incyte Corporation (INCY)

Market Closed
10 Jun, 20:00
NASDAQ (NGS) NASDAQ (NGS)
$
70. 07
+0.18
+0.26%
$
13.05B Market Cap
33.14 P/E Ratio
0% Div Yield
1,917,144 Volume
3.57 Eps
$ 69.89
Previous Close
Day Range
69.65 70.96
Year Range
53.56 83.95
Earnings results expected in 48 days

Summary

INCY closed today higher at $70.07, an increase of 0.26% from yesterday's close, completing a monthly increase of 12.98% or $8.05. Over the past 12 months, INCY stock gained 0.57%.
INCY is not paying dividends to its shareholders.
The last earnings report, released on Apr 28, 2025, missed the consensus estimates by -0.84%. On average, the company has fell short of earnings expectations by -0.32%, based on the last three reports. The next scheduled earnings report is due on Jul 28, 2025.
Incyte Corporation has completed 2 stock splits, with the recent split occurring on Sep 01, 2000.
The company's stock is traded on 9 different exchanges and in various currencies, with the primary listing on NASDAQ (NGS) (USD).
Want to track INCY and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

INCY Chart

Chart

Empty chart
The chart has 2 Y axes displaying values, and values.
Loading, please wait...
End of interactive chart.
Why Is Incyte (INCY) Up 3.6% Since Last Earnings Report?

Why Is Incyte (INCY) Up 3.6% Since Last Earnings Report?

Incyte (INCY) reported earnings 30 days ago. What's next for the stock?

Zacks | 1 week ago
Incyte to Present at Upcoming Investor Conference

Incyte to Present at Upcoming Investor Conference

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it will present at the Goldman Sachs Healthcare Conference on Monday, June 9, 2025 at 11:20 am (ET). The presentation will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days. About Incyte A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs. Through the discovery, development.

Businesswire | 2 weeks ago
Incyte Gets FDA Approval for Zynyz in New Cancer Indication

Incyte Gets FDA Approval for Zynyz in New Cancer Indication

The FDA approves INCY's Zynyz both as monotherapy and in combination with chemotherapy for treating advanced anal cancer.

Zacks | 3 weeks ago

Incyte Corporation Dividends

INCY is not paying dividends to its shareholders.

Incyte Corporation Earnings

28 Jul 2025 (48 Days) Date
-
Cons. EPS
-
EPS
28 Apr 2025 Date
0.84
Cons. EPS
-
EPS
11 Feb 2025 Date
1.55
Cons. EPS
1.43
EPS
29 Oct 2024 Date
1.07
Cons. EPS
1.07
EPS
30 Jul 2024 Date
-
Cons. EPS
-
EPS
INCY is not paying dividends to its shareholders.
28 Jul 2025 (48 Days) Date
-
Cons. EPS
-
EPS
28 Apr 2025 Date
0.84
Cons. EPS
-
EPS
11 Feb 2025 Date
1.55
Cons. EPS
1.43
EPS
29 Oct 2024 Date
1.07
Cons. EPS
1.07
EPS
30 Jul 2024 Date
-
Cons. EPS
-
EPS

Incyte Corporation (INCY) FAQ

What is the stock price today?

The current price is $70.07.

On which exchange is it traded?

Incyte Corporation is listed on NASDAQ (NGS).

What is its stock symbol?

The ticker symbol is INCY.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, the market cap is 13.05B.

What is the earnings per share?

The EPS is 0.

When is the next earnings date?

The next earnings report will release on Jul 28, 2025.

Has Incyte Corporation ever had a stock split?

Incyte Corporation had 2 splits and the recent split was on Sep 01, 2000.

Incyte Corporation Profile

Biotechnology Industry
Healthcare Sector
Mr. Herve Hoppenot CEO
NASDAQ (NGS) Exchange
45337C102 Cusip
US Country
2,617 Employees
- Last Dividend
1 Sep 2000 Last Split
4 Nov 1993 IPO Date

Overview

Incyte Corporation is a prominent biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapeutics. With a broad interest in hematology/oncology and inflammation and autoimmunity sectors, Incyte operates both within the United States and on an international scale. Originally founded in 1991 and known as Incyte Genomics Inc., the company underwent a name change to Incyte Corporation in March 2003. It has established a formidable presence in the pharmaceutical industry, not only through the inception of proprietary drugs but also via strategic collaborations and in-license agreements with other leading biotech entities such as Novartis, Lilly, Agenus, Merus, MacroGenics, Syndax, and China Medical System Holdings Limited. Headquartered in Wilmington, Delaware, Incyte holds a pivotal role in pushing forward the boundaries of medical research and patient care in critical disease areas.

Products and Services

  • JAKAFI (ruxolitinib)

    A cornerstone in Incyte's portfolio, JAKAFI is approved for the treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease. Its mechanism targets aberrant signaling pathways to curb disease progression.

  • MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab)

    Designed for patients with relapsed or refractory diffuse large B-cell lymphoma; a testament to Incyte's commitment to addressing unmet needs in oncology.

  • PEMAZYRE (pemigatinib)

    Acts as a fibroblast growth factor receptor kinase inhibitor, targeting oncogenic drivers in various liquid and solid tumor types, showcasing Incyte's innovative approach in targeted cancer therapy.

  • ICLUSIG (ponatinib)

    Approved for chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia, providing a targeted therapeutic option for these hematologic cancers.

  • ZYNYZ (retifanlimab-dlwr)

    This drug is deployed in the treatment of adults with metastatic or recurrent locally advanced Merkel cell carcinoma, underscoring the company's dedication to rare oncology indications.

  • OPZELURA cream

    Marketed for the treatment of atopic dermatitis, this offering diversifies Incyte's portfolio into the dermatological field, addressing a common yet challenging chronic skin condition.

In addition to these marketed products, Incyte's clinical stage pipeline showcases a robust commitment to innovation through a variety of compounds under development, including retifanlimab for additional cancers, axatilimab for chronic GVHD, and a range of molecules designed to tackle solid tumors. The depth and breadth of Incyte's clinical research reflect its continuous pursuit of therapeutic advances to improve patient outcomes in areas of significant unmet medical need.

Contact Information

Address: 1801 Augustine Cut-Off
Phone: 302 498 6700